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Abstract. Background/Aim: Axillary surgery of breast
cancer patients is undergoing a paradigm shift, as axillary
lymph node dissection’s (ALND) usefulness is being
questioned in the treatment of patients with tumor-positive
sentinel lymph node biopsy (SLNB). The aim of this study
was to investigate the overall survival (OS) and relapse-free
survival (RFS) of patients with positive SLNB treated with
ALND or not. Patients and Methods: We investigated 617
consecutive patients with cN0 operable breast cancer with
positive SLNB undergoing mastectomy or conservative
surgery. A total of 406 patients underwent ALND and 211
were managed expectantly. Results: No significant difference
in OS and RFS was found between the two groups. The
incidence of loco-regional recurrence in the SLNB-only
group and the ALND group was low and not significant.
Conclusion: The type of breast cancer surgery and the
omission of ALND does not improve OS or RSF rate in cases
with metastatic SLN. 
Sentinel lymph node biopsy (SLNB) is the standard
technique used for nodal staging in all patients with invasive
breast cancer and clinically-negative axillary lymph nodes.
Nowadays, SLNB has replaced conventional axillary lymph
node dissection (ALND) as a standard procedure (1-4). For
years, axillary dissection was considered the standard
procedure in cases with positive SLNB for macrometastasis
(>2 mm) (5-6). 
The rationale behind this procedure is the control of local
recurrence and the increase of overall survival (OS).
However, several authors have questioned the actual role of
ALND in cases with positive SLNB. This procedure can lead
to severe side effects such as lymphedema and reduction of
limb and/or shoulder function in 5-39% of cases (7-9). 
The American College of Surgeons Oncology Groups
(ACOSOG) Z0011 Study showed that there was no
statistically significant difference in local recurrence-free
survival patients undergoing breast-conserving surgery and
avoiding ALND at 6.3 years and at 9.25 years of follow-up
compared with patients treated with ALND (10-12). Similar
results were observed in the AMAROS trial (13) and in the
IBCSG 23-01 trial (14). A recent meta-analysis that included
the above-mentioned trials (ACOSOG Z011, IBCSG 23-01,
AMAROS) and two other studies (OTOSAOR and AATRM-
048-13-2000) did not show differences in survival or
recurrence between ALND, SLNB or axillary RT, observing
more local complications in patients treated with ALND
(15). Bilimoira et al. (16) reviewed 20,075 SLNB-positive
breast cancer patients from the National Cancer Database
and Yi et al. (17) reviewed 26,986 SLNB-positive breast
cancer patients from the surveillance, epidemiology and end
results (SEER) database: both Authors did not show any
significant differences in OS rates between patients treated
with SLNB only and SLNB plus ALND. However,
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proposing ALND only in selected cases is still a matter of
debate. The purpose of this retrospective study was to
evaluate the overall survival (OS) and relapse free-survival
(RFS) of patients with positive SLNB treated with ALND or
not, and the impact of the type of breast surgery (mastectomy
or conservative surgery).
Patients and Methods
From our institutional database, 2,329 consecutive women with
invasive breast cancer treated with conservative surgery or
mastectomy and SLNB from December 2004 to October 2014 were
retrospectively identified. Patients who had neoadjuvant treatment
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Table I. Characteristics of 617 patients with operable breast cancer and positive sentinel lymph node positive divided into axillary dissection (ALND)
and sentinel lymph node biopsy (SLNB) only. 
Characteristic                                                                                         SLNB only (n=211)                       ALND (N=406)                             p-Value
Age, year, median (standard deviation)                                                       57 (±11.5)                                   54 (±11.5)                                    0.09
Tumor size, mm, median (standard deviation)                                             19 (±7.9)                                    22 (±10.2)                                    0.07
Pathologic T stage                                                                                                                                                                                                   0.08
  T1                                                                                                                118 (56%)                                   211 (52%)
  T2                                                                                                                 82 (43%)                                    189 (46%)
  T3                                                                                                                   1 (1%)                                         6 (2%)
SLN metastasis                                                                                                                                                                                                       0.01
  Micrometastasis (<2 mm)                                                                         115 (54.5%)                                 84 (20.6%)
  Macrometastasis (>2 mm)                                                                         95 (45.5%)                                 322 (79.4%)
SLN metastasis size, mm median (standard deviation)                               2.2 (±2.6)                                    4.3 (±5.4)                                  <0.001
Number of positive lymph nodes in axillary dissection
  0                                                                                                                        N.A.                                       217 (53%)
  1-3                                                                                                                    N.A.                                        134 (33%)
  >4                                                                                                                     N.A.                                         55 (14%)
Histology                                                                                                                                                                                                                 0.269
  Ductal                                                                                                          161 (76%)                                  287 (71%)
  Lobular                                                                                                         30 (15%)                                     82 (20%)
  Special type                                                                                                   20 (9%)                                       37 (9%)
Grade                                                                                                                                                                                                                       0.01
  G1                                                                                                                 60 (29%)                                     42 (20%)
  G2                                                                                                                104 (49%)                                   205 (51%)
  G3                                                                                                                 47 (22%)                                    159 (39%)
LVI                                                                                                                                                                                                                         <0.001
  Yes                                                                                                                94 (55%)                                    292 (72%)
  No                                                                                                                117 (45%)                                   114 (28%)
ER                                                                                                                                                                                                                            0.446
  Positive                                                                                                        190 (90%)                                   352 (87%)
  Negative                                                                                                       21 (10%)                                     54 (13%)                                       
PgR                                                                                                                                                                                                                          0.769
  Positive                                                                                                        175 (83%)                                   352 (87%)
  Negative                                                                                                       36 (10%)                                     54 (13%)
HER2-neu                                                                                                                                                                                                                0.01
  Positive                                                                                                         26 (12%)                                     72 (26%)
  Negative                                                                                                      154 (73%)                                   235 (58%)
  Unknown                                                                                                      31 (15%)                                     99 (16%)
Adjuvant chemotherapy                                                                                                                                                                                       <0.001
  Yes                                                                                                                85 (40%)                                    321 (78%)
  No                                                                                                                126 (60%)                                    85 (12%)
Adjuvant hormonotherapy                                                                                                                                                                                      0.487
  Yes                                                                                                               187 (87%)                                   346 (84%)
  No                                                                                                                 24 (13%)                                     60 (16%)
Adjuvant radiotherapy                                                                                                                                                                                            0.461
  Yes                                                                                                               169 (80%)                                   335 (81%)
  No                                                                                                                 42 (20%)                                     71 (19%)
Surgery                                                                                                                                                                                                                    0.763
  Conservative                                                                                               176 (83%)                                   337 (83%)
  Mastectomy                                                                                                  35 (17%)                                     69 (17%)
ER: Estrogen receptor; PgR: progesterone receptor. LVI: lymphovascular invasion; N.A.: not available.
or previous axillary surgery were excluded. In 629 cases SLN was
metastatic. Twelve patients lost to follow-up were excluded, leaving
617 cases. ALND was performed in 406 patients (ALND group) and
211 were managed expectantly (SLNB only group). 
Primary tumor specific variables included: pathological tumor
size, histological and nuclear grade, histological type (ductal,
lobular, special type), estrogen and progesterone receptor status
(ER, PgR), human epidermal growth factor receptor 2 (HER-2)
status, presence of lymphovascular invasion (LVI) and SLN
metastasis size. We also considered the type of breast surgery
(conservative surgery or mastectomy) and adjuvant treatments
(hormone therapy, chemotherapy and/or radiotherapy).
In the ALND group, 69 mastectomies and 337 conservative
breast surgery interventions were performed, while in the SLNB
only group 35 patients underwent mastectomy and 176 conservative
breast surgery. In this cohort of patients, SLN was identified with
lymphoscintigraphy (using 99mTc-labeled sulphide colloid); in the
case of failure, SLN was identified with a peritumoral or periareolar
injection of 2 to 5 ml vital dye (Patent blue V).  In cases with
negative SLN on frozen section, the SLN was examined on multiple
sections stained with hematoxylin eosin and analysed by
immunohistochemistry with anti-cytokeratin AE1/3 antibodies. A
dedicated breast pathologist (AR) analyzed all cases (tumors
histology and SLN).
For the first 5-year follow-up period, outpatient visits took place
every 6 months, while from the 6th to the 10th year annually. A
mammography and ultrasound breast examination were performed
annually and, in case of suspicion of recurrence, further diagnostic
tests were performed (abdominal/chest computed tomography, bone
scan and/or positron emission tomography as appropriate). Disease
status or cause of death was ascertained from clinical findings,
phone follow-up or using Cancer Registry data of our Region
(Piedmont Cancer Registry, Centre for Epidemiology and
Prevention in Oncology in Piedmont, Turin, Italy). Overall the
median follow-up was 84.4 months, for the ALND group was 90
months and for the SLNB only group was 74 months.
Statistical analysis. IBM® SPSS® v.23 (SPSS Inc. Chicago, IL,
USA) software was used to conduct the statistical analyses. We
analyzed the differences between ALND Group and SLNB only
Group using Pearson’s chi square test or Fisher’s exact test for
categorical variables; while numerical variables were compared with
variance analysis (ANOVA). Survival and cumulative risk of
recurrence for each of these groups were estimated using the
Kaplan–Meier method and compared using the log-rank test. Cox
proportional hazards regression was used for multivariate analysis.
Variables included in the multivariate analysis were those found to
be statistically significant in the univariate analyses. All reported
values are two sided, and p<0.05 was considered statistically
significant.
Results
Patient and disease characteristics and postoperative treatments
of both groups are summarized in Table I. The ALND group,
compared with the SLNB only group, had more
macrometastasis (79.9% vs. 45.5%, p<0.01), larger SLN
metastasis size (4.3 mm vs. 2.2 mm, p<0.001), more positive
LVI (72% vs. 55%, p<0.001), higher histological grade (G3)
(39% vs. 22%, p<0.01) and more HER2-neu overexpression
(26% vs. 12%, p<0.001). However, no significant differences
between the two groups in median age, media tumor size,
pathologic T stage, histotype and hormonal receptor status
were seen. The distribution of the type of breast surgery
(mastectomy or conservative surgery) does not differ
statistically between the two groups. More patients in the
ALND group received chemotherapy (78% vs. 37%, p<0.001),
whereas there were no differences in the use of adjuvant
hormone therapy and radiotherapy. Furthermore, we did not
observe significant differences in loco-regional recurrences,
onset of contralateral breast disease and cancer related deaths,
while there were more distant metastases in the ALND group
(Table II). In 217 cases of the ALND group (53.4%) SLN was
the only node involving metastasis. The median follow-up was
84.4 months. OS was 87.8% in the ALND group and 94.8% in
the SLNB only group (with a non-significant difference, log
rank p=0.07; Figure 1A).
The univariate analysis (Table III) showed that tumor size,
SLN metastasis size, LVI, negative PgR and ER, positive
HER2-neu, high grade (G3), lobular histotype compared with
ductal histotype and the omission of hormonal therapy are
related to worse OS, while in the multivariate analysis LVI,
negative PgR and histology were not related with OS.
The relapse-free survival rate (RFS) (loco-regional and
distant combined) was 82.3% in the ALND group and 87.1%
in the SLNB only group (not significant, log rank p=0.51)
(Figure 1B).
By analysing only distant metastasis, we obtained an
84.7% RFS rate in the ALND group and 90.9% RFS rate in
the SLNB only group (log rank p=0.14). No difference was
found in loco-regional RFS rate between the ALND group
and the SLNB only group (respectively 98% and 95.7%, log
rank p=0.06).
Using Cox regression model, tumor size, SLN metastasis
size, LVI, negative PgR and ER, positive HER2-neu, high
grade (G3), ductal histotype vs. lobular and special types
were able to predict recurrence of breast cancer. The
multivariate analysis confirmed all predictors except histotype
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Table II. Events in 617 patients with operable breast cancer and positive
SLNB.
Events                                                SLNB only        ALND      p-Value
                                                              (n=211)          (N=406)
Ipsilateral breast tumor recurrence       9 (4.2%)         8 (1.9%)        0.08
Ipsilateral axillary disease                  3 (1.4%)         1 (0.2%)        0.12
Contralateral breast cancer                 3 (1.4%)         6 (1.5%)        0.84
Distant metastasis                              19 (9.0%)       62 (15.2%)      0.03
Died for disease                                 11 (5.2%)       50 (12.3%)      0.07
Died for other causes                          4 (1.9%)         7 (1.7%)        0.09
and negative PgR. The same predictors at multivariate
analysis could be observed for OS except for SLN metastasis
size and LVI.
Discussion
The main goal of this study was to compare the OS and RSF
of patients with positive SLNB treated with ALND compared
to patients treated with SLNB only. This is a retrospective
study subject to selection bias: in 211 patients (SLNB only
group) axillary dissection was omitted because they had less
tumor burden in SLN and were less likely to receive
chemotherapy than ALND group. However, differences in the
biological characteristics of tumors between the two groups
are present in some previous non randomized clinical trials
studies (18-20), which analyzed the differences in OS and
recurrence between patients with positive SLNB who
underwent axillary dissection or not. Despite the retrospective
nature of this study, the axillary recurrence rate of 1.4% (3
cases) in our series, is comparable to the one reported in RCTs
(10-14) in patients without palpable axillary lymph nodes and
positive SLNB that did not undergo ALND. Moreover, we did
not find any statistical differences between the two groups
concerning the ipsilateral breast recurrence (1.9% in AND
group vs. 4.2% in SLNB only group) in support of the limited
therapeutic efficacy of axillary dissection on the loco-regional
control. We found more distant metastasis in the ALND group
compared to the SLNB only group, but without having a
significant impact on RFS (log rank p=0.14); the higher
number of events can be explained by a selection bias in the
ALND group (more patients with worst biological prognostic
factors than in the SNB only group). In the ALND group, SLN
was the only metastatic lymph node in over half of cases. A
similar trend was reported in the meta-analysis of Kim (21),
where 47% of cases with ALND had no further metastases in
the lymph nodes removed. Therefore, about 50% of patients
received a useless procedure. We also investigated the
potential impact of the type of breast surgery on OS and RFS.
Currently, OS and RFS data on mastectomies are derived from
retrospective studies: Fu et al. (22) compared 214 patients
pN1 treated by mastectomy with SLNB plus RT versusALND
and did not observe any significant differences in terms of OS
and RFS; similar findings were observed in a study by Snow
et al (23) with no significant differences in OS and RFS after
10-years of follow-up. Furthermore, similar results were
obtained by Fitz Sullivan et al. (24) in a retrospective study
of 525 patients with invasive breast cancer and positive SLNB
treated with mastectomy. Our results confirmed this trend. In
April 2014, Roozendaal et al. (25) registered a non-inferiority
randomized controlled trial (BOOG 2013-7) to study and
clarify the impact of ALND on OS and RFS in patients with
T1-2 N0 breast cancer treated with mastectomy, who also had
a maximum of three SLNs containing micro and/or
macrometastases. The only adjuvant therapy playing a
significant role on OS and RFS is hormone therapy, probably
due to the worse prognosis of tumors with negative hormone
receptors. At multivariate analysis, the biological features were
significant independent predictors of poorer OS and RFS,
suggesting that tumor biology, rather than type of axillary and
breast surgery, is predictive for the prognosis. In conclusion,
our results support the omission of ALND in patients with
positive SLNB, as no significant benefit in terms of OS and
in vivo 33: 1941-1947 (2019)
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Figure 1. Overall survival and cumulative risk of recurrence of pN1 patients with ALND versus patients with no ALND. A) Breast cancer survival
(p=0.07). B) Cumulative risk of recurrence (p=0.43). ALND: Axillary lymph node dissection. 
RFS was found, especially for loco-regional control of the
disease. This procedure should be reserved for high-risk
patients or in case of clinical metastatic axillary sentinel
lymph node (higher tumor burden in SLN is related to worst
prognosis) (24). Results from this study confirm what has
been previously reported by several other studies (including
RCTs), suggesting that most patients with invasive breast
cancer and metastatic SLN do not benefit from ALND.
Indeed, biological prognostic factors and adequate systemic
therapy are probably more important than the type of breast
and axillary surgery to reduce disease mortality and the
recurrence rate. Further studies are required to identify
positive SLNB patients who can benefit from ALND, in order
to reduce the number of patients undergoing axillary surgery,
a procedure with serious comorbidities that increase operative
times and health system costs.
Arisio et al: Axillary Dissection and Positive Sentinel Lymph Nodes in Breast Cancer 
1945
Table III. Cox regression analysis of treatments and biological tumor characteristics on recurrence and breast cancer death.
Characteristic                                                                 Any Recurrence                                                                    Breast cancer death
                                                                 Univariate                               Multivariate                               Univariate                               Multivariate
                                                HR (95%CI)       p-Value        HR (95%CI)       p-Value        HR (95%CI)         p-Value        HR (95%CI)      p-Value
Age (per year)                     0.99 (0.97-1.00)       0.13                                                          0.98 (0.95-1.04)         0.12
Tumor size                           1.05 (1.03-1.06)    <0.001*     1.03 (1.01-1.05)    <0.001*     1.01 (1.02-1.05)     <0.001*     1.04 (1.02-1.06)   <0.001*
SLN metastasis size            1.07 (1.04-1.11)    <0.001*     1.04 (1.01-1.07)     0.001*      1.08 (0.96-1.20)         0.36
Axillary dissection
  Yes                                               1.00                                                                                             1.00                       
  No                                      0.86 (0.55-1.34)       0.51                                                          0.55 (0.29-1.06)         0.07
Adjuvant chemotherapy
  Yes                                               1.00                                                                                             1.00
  No                                      1.25 (0.80-1.96)       0.33                                                          1.48 (0.79-2.66)         0.22
Adjuvant radiotherapy
  Yes                                               1.00                                                                                             1.00
  No                                      1.59 (0.91-2.50)       0.10                                                          0.97 (0.46-2.05)         0.94
  
Adjuvant hormonotherapy
  Yes                                               1.00                                          1.00                                           1.00                                            1.00
  No                                      2.92 (1.36-4.32)     0.003*     6.62 (2.36-18.50)   <0.001*     2.19 (1.35-3.56)       0.002*     7.31 (1.82-28.36)   <0.05*
Breast surgery
  Mastectomy                                1.00                                                                                             1.00 
  Conservative                     1.82 (0.92-2.94)       0.06                                                          1.64 (0.87-3.11)         0.13 
ER
  Positive                                       1.00                                          1.00                                          1.00                                            1.00 
  Negative                            2.02 (1.36-3.02)    <0.001*    5.05 (1.95-13.1)    <0.001*    2.02 (1.36-3.02)        0.01*       3.78 (1.07-13.4)     0.03* 
PgR
  Positive                                       1.00                                          1.00                                          1.00                                            1.00 
  Negative                            1.96 (1.30-2.80)    <0.001*    1.63 (0.83-3.20)       0.15        1.90 (1.35-3.18)        0.01*       1.51 (0.69-13.4)     0.563 
HER2-neu
  Negative                                      1.00                                          1.00                                          1.00                                            1.00 
  Positive                             2.02 (1.36-3.02)     <0.03*     1.19 (1.30-2.91)      0.02*       3.94 (1.78-8.75)     <0.001*     3.60 (1.72-7.79)   <0.001*
LVI
  No                                               1.00                                          1.00                                          1.00                                            1.00 
  Yes                                     2.54 (1.37-4.72)    <0.001*    2.67 (1.25-5.70)      0.01*       3.87 (1.84-8.15)     <0.001*     1.79 (0.74-4.32)      0.19 
Grade
  G1                                               1.00                                          1.00                                          1.00                                            1.00 
  G2                                      2.04 (0.85-4.76)       0.10                                                          1.47 (0.50-4.42)         0.46 
  G3                                      5.34 (2.30-12.4)    <0.001*     4.9 (2.19-11.3)     <0.001*     5.34 (2.30-12.4)     <0.001*     5.31 (2.35-12.4)   <0.001*
Histology
  Ductal                                          1.00                                          1.00                                          1.00                                            1.00 
  Lobular                              0.43 (0.23-0.80)      0.02*       0.23 (0.65-1.46)       0.34        0.50 (0.25-1.01)         0.18        1.20 (0.22-3.52)      0.20
  Special type                      0.45 (0.26-0.79)      0.02*       1.03 (0.56-1.89)       0.73        0.46 (0.38-0.79)        0.03*       1.49 (0.50-4.40)      0.47
HR: Hazard ratio; CI: confidence interval; ER: estrogen receptor; PgR: progesterone receptor; LVI: lymphovascular invasion. *Statistically
significant.
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